Hepatitis B & C Treatment in India 2026: Affordable Cure with DAA Drugs & Expert Hepatologists
The WHO's global hepatitis elimination target for 2030 is ambitious: a 90% reduction in new infections and 65% reduction in mortality from hepatitis B and C. India is central to that mission — both as a country with significant domestic hepatitis burden and as the world's primary manufacturer of the generic direct-acting antiviral (DAA) drugs that make hepatitis C cure accessible globally. For African patients who cannot afford brand-name DAAs at home or lack access to adequate hepatology care, India offers something extraordinary: a cure for hepatitis C for USD 200 and expert hepatology management of hepatitis B at a fraction of Western costs.
TL;DR: Hepatitis C cure with DAA drugs costs USD 150–300 in India for a 12-week course. Success rates (SVR) are 95–99%. Hepatitis B cannot be cured but can be effectively suppressed with USD 10–30/month antivirals. Many patients only need 5–10 days in India before completing treatment at home.
The Global Hepatitis Burden
Viral hepatitis B and C together cause more deaths than HIV/AIDS, tuberculosis, or malaria. An estimated 296 million people live with chronic hepatitis B globally and 58 million with hepatitis C. Sub-Saharan Africa bears the highest hepatitis B burden in the world, with prevalence of 6–8% in the general population in some regions.
Yet treatment uptake remains tragically low — primarily because of cost. Sofosbuvir, the backbone of hepatitis C cure regimens, cost USD 84,000 per 12-week course when Gilead launched it in the USA in 2014. India's generic pharmaceutical industry changed this equation irrevocably. Indian-manufactured sofosbuvir generics received WHO prequalification and quickly reduced the global treatment price to under USD 300 per course.
Hepatitis C: Mechanisms and the DAA Revolution
Hepatitis C is a blood-borne RNA virus with 6 major genotypes. Genotype 1 is most common in North America and Europe; genotypes 4 and 5 predominate in sub-Saharan Africa and Egypt; genotype 3 is common in Pakistan and India.
Prior to 2014, hepatitis C treatment was 48 weeks of pegylated interferon injections plus ribavirin — poorly tolerated, moderately effective (50–70% cure), and expensive. DAAs changed everything.
Current DAA Regimens Available in India
| Regimen | Drugs | Duration | Cost India (USD) | Genotypes |
|---|---|---|---|---|
| Sofosbuvir/Velpatasvir | Epclusa generic | 12 weeks | 150–250 | All (pangenotypic) |
| Sofosbuvir/Daclatasvir | Generic + generic | 12 weeks | 200–300 | 1, 2, 3, 4 |
| Sofosbuvir/Ledipasvir | Harvoni generic | 12 weeks | 180–280 | 1, 4, 5, 6 |
| Glecaprevir/Pibrentasvir | Mavyret generic | 8 weeks | 300–500 | All (pangenotypic) |
All these drugs are manufactured to WHO prequalification standards in India. Their efficacy is equivalent to brand-name versions — the same molecules, same manufacturing standards, dramatically different price.
SVR Rates
Sustained virological response (SVR) at 12 weeks post-treatment is the definition of cure — undetectable HCV RNA for 12 weeks after completing therapy. With current pangenotypic regimens:
- Treatment-naive, no cirrhosis: SVR 97–99%
- Treatment-naive, compensated cirrhosis: SVR 92–96%
- Treatment-experienced (prior interferon): SVR 93–97%
- Decompensated cirrhosis: SVR 85–92% (requires sofosbuvir/velpatasvir + ribavirin)
These outcomes are identical to brand-name drugs in registered clinical trials.
The India Treatment Process for Hepatitis C
Most hepatitis C patients can complete their India visit in 5–10 days:
Day 1–2: Hepatology consultation, baseline blood tests (HCV RNA quantification, genotype, liver function, renal function, full blood count), FibroScan or liver biopsy if cirrhosis staging required, HIV test.
Day 2–3: Regimen selection based on genotype, cirrhosis status, and renal function. Prescription dispensed.
Day 3–5: Treatment initiation, first doses confirmed, any side effects identified.
Day 5–10: Tolerance confirmed, prescription for 12-week course dispensed, customs documentation for international travel prepared.
The 12-week treatment course continues at home. Arodya coordinates:
- Week 4 viral load monitoring (should show >2 log reduction or undetectable)
- End-of-treatment viral load
- SVR12 test (12 weeks after completing treatment)
- Teleconsultation with Indian hepatologist at each monitoring point
Hepatitis B: Management, Not Cure
Hepatitis B virus (HBV) cannot yet be functionally cured in most patients, though research into agents targeting HBV cccDNA (the viral reservoir) is active. The current treatment goal is functional cure — HBsAg loss — which a minority of patients achieve over years of treatment, or more practically, durable viral suppression preventing progression to cirrhosis and liver cancer.
Who Needs Treatment?
Not all HBV carriers need antiviral therapy. Treatment is indicated for:
- HBV DNA > 2,000 IU/mL with elevated ALT
- Significant fibrosis on liver biopsy or non-invasive testing (FibroScan F2+)
- HBV DNA > 20,000 IU/mL regardless of ALT
- HBsAg-positive patients undergoing immunosuppressive therapy
- Patients with HDV (hepatitis D) co-infection
Antiviral Options and Costs in India
| Drug | Monthly Cost India (USD) | Monthly Cost USA (USD) | Duration |
|---|---|---|---|
| Tenofovir disoproxil (TDF) | 10–20 | 500–800 | Indefinite |
| Tenofovir alafenamide (TAF) | 30–60 | 800–1,200 | Indefinite |
| Entecavir | 15–30 | 500–900 | Indefinite |
TDF is the preferred first-line agent for most patients. TAF has a better renal and bone safety profile, preferred for patients over 60 or with renal impairment. Both achieve HBV DNA suppression to undetectable levels in >95% of patients within 48 weeks.
HBV and Liver Cancer Surveillance
Patients with chronic HBV require 6-monthly hepatocellular carcinoma (HCC) surveillance with liver ultrasound and AFP. Indian hepatology departments include structured surveillance programmes. Arodya coordinates the handover to local surveillance providers when patients return home.
Hepatitis C and B Co-infection
HBV-HCV co-infection is rare but managed at Indian hepatology centres. Treating hepatitis C in co-infected patients carries a risk of HBV reactivation — HBsAg-positive or anti-HBc-positive patients starting DAA therapy require HBV prophylaxis (TDF or entecavir) simultaneously.
For patients with HIV-HBV or HIV-HCV co-infection, drug interaction assessment is critical. Indian HIV specialists and hepatologists collaborate on co-infected patients — a combination not available in many African referral settings.
Getting Your Medications Through Customs
Carrying prescription medications internationally requires documentation. Arodya provides:
- Doctor's prescription on headed hospital paper
- Certificate of treatment explaining the medication and its necessity
- Customs declaration support letter
Most African customs authorities accept these documents without issue for personal treatment quantities. Arodya has managed hundreds of patients transporting DAA medications through customs at African airports.
For comparison of treatment costs across conditions, see our cancer treatment cost comparison India versus Western countries. For patients with liver disease progressing to cirrhosis and needing transplant assessment, see our heart transplant guide which covers organ transplant logistics.
Ready to access affordable hepatitis treatment? Start your consultation request with Arodya — share your HCV RNA result, genotype if known, and latest liver function tests for a personalised treatment plan.
